Company news
Neuphoria Therapeutics Inc. (NASDAQ:NEUP) news
Neuphoria Therapeutics Inc. news releases on 6ix. Latest, Jul 23, 2026: Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Press releases & updates
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
July 22, 2026
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
June 26, 2026
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
December 8, 2025
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
December 4, 2025
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
December 2, 2025
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
December 1, 2025
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
November 24, 2025
Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value
November 11, 2025
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
October 27, 2025
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
October 20, 2025
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
September 29, 2025
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
September 4, 2025
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 28, 2025
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
May 27, 2025
Neuphoria Provides First Quarter 2025 Business Updates
May 20, 2025
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
April 15, 2025
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
March 3, 2025
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
February 11, 2025
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
December 22, 2024
Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation
December 15, 2024
Results of Scheme Meeting
December 11, 2024
Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
December 8, 2024
Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
December 2, 2024
Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States
December 1, 2024
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement
November 7, 2024
Bionomics to Present at the 2024 CNS Summit
November 6, 2024
Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program
November 3, 2024
Bionomics to Present at the ThinkEquity Conference
October 22, 2024
Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
October 13, 2024
Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
October 6, 2024
Bionomics Limited announces intention to re-domicile to the United States
September 30, 2024
Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 2, 2024
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder
July 30, 2024
Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
July 28, 2024
Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder
July 17, 2024
Bionomics Limited Announces Private Placement of up to $70.0 Million
May 30, 2024
Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 19, 2024
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
March 20, 2024
Bionomics to Present at the 2024 BIO CEO & Investor Conference
February 21, 2024
Bionomics Provides a Review of 2023 and of 2024 Plans
January 21, 2024
Bionomics to Present at Biotech Showcase™ 2024
January 4, 2024
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting
December 5, 2023
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
October 15, 2023
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
September 27, 2023
Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD
September 13, 2023
Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210
August 22, 2023
Quarterly Activities and Cashflow Report
July 30, 2023
Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)
July 24, 2023
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth
July 2, 2023
Bionomics to Present at Upcoming June Investor Conferences
June 14, 2023